335 related articles for article (PubMed ID: 37653142)
1. Clinical and translational advances in ovarian cancer therapy.
Konstantinopoulos PA; Matulonis UA
Nat Cancer; 2023 Sep; 4(9):1239-1257. PubMed ID: 37653142
[TBL] [Abstract][Full Text] [Related]
2. Epithelial ovarian cancer: Review article.
Sambasivan S
Cancer Treat Res Commun; 2022; 33():100629. PubMed ID: 36127285
[TBL] [Abstract][Full Text] [Related]
3. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.
Buechel M; Herzog TJ; Westin SN; Coleman RL; Monk BJ; Moore KN
Ann Oncol; 2019 May; 30(5):721-732. PubMed ID: 30887020
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.
Gockley A; Melamed A; Cronin A; Bookman MA; Burger RA; Cristae MC; Griggs JJ; Mantia-Smaldone G; Matulonis UA; Meyer LA; Niland J; O'Malley DM; Wright AA
Am J Obstet Gynecol; 2019 Dec; 221(6):625.e1-625.e14. PubMed ID: 31207237
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
[No Abstract] [Full Text] [Related]
6. New developments in molecular targeted therapy of ovarian cancer.
Guan LY; Lu Y
Discov Med; 2018 Nov; 26(144):219-229. PubMed ID: 30695681
[TBL] [Abstract][Full Text] [Related]
7. First-Line Management of Advanced High-Grade Serous Ovarian Cancer.
Mahmood RD; Morgan RD; Edmondson RJ; Clamp AR; Jayson GC
Curr Oncol Rep; 2020 Jun; 22(6):64. PubMed ID: 32494876
[TBL] [Abstract][Full Text] [Related]
8. Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer.
Gourley C; Bookman MA
J Clin Oncol; 2019 Sep; 37(27):2386-2397. PubMed ID: 31403859
[No Abstract] [Full Text] [Related]
9. [The molecular biology of epithelial ovarian cancer].
Leary A; Pautier P; Tazi Y; Morice P; Duvillard P; Gouy S; Uzan C; Gauthier H; Balleyguier C; Lhommé C
Bull Cancer; 2012 Dec; 99(12):1161-73. PubMed ID: 23238064
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
11. Management and Treatment of Recurrent Epithelial Ovarian Cancer.
Armbruster S; Coleman RL; Rauh-Hain JA
Hematol Oncol Clin North Am; 2018 Dec; 32(6):965-982. PubMed ID: 30390768
[TBL] [Abstract][Full Text] [Related]
12. New medical approaches in advanced ovarian cancer.
Corrado G; Palluzzi E; Bottoni C; Pietragalla A; Salutari V; Ghizzoni V; Distefano M; Scambia G; Ferrandina G
Minerva Med; 2019 Aug; 110(4):367-384. PubMed ID: 31124637
[TBL] [Abstract][Full Text] [Related]
13. SEOM clinical guideline in ovarian cancer (2020).
Redondo A; Guerra E; Manso L; Martin-Lorente C; Martinez-Garcia J; Perez-Fidalgo JA; Varela MQ; Rubio MJ; Barretina-Ginesta MP; Gonzalez-Martin A
Clin Transl Oncol; 2021 May; 23(5):961-968. PubMed ID: 33515422
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Rare Epithelial Ovarian Tumors.
Cobb LP; Gershenson DM
Hematol Oncol Clin North Am; 2018 Dec; 32(6):1011-1024. PubMed ID: 30390757
[TBL] [Abstract][Full Text] [Related]
15. [Progress in preoperative evaluation methods regarding cytoreduction in patients with advanced ovarian cancer].
Liu J; Zhang K
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Jul; 42(7):854-859. PubMed ID: 28845013
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and Treatment of Ovarian Cancer.
Orr B; Edwards RP
Hematol Oncol Clin North Am; 2018 Dec; 32(6):943-964. PubMed ID: 30390767
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic Pathways and Targeted Therapies in Ovarian Cancer.
Lliberos C; Richardson G; Papa A
Biomolecules; 2024 May; 14(5):. PubMed ID: 38785992
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial.
Moreno V; Barretina-Ginesta MP; García-Donas J; Jayson GC; Roxburgh P; Vázquez RM; Michael A; Antón-Torres A; Brown R; Krige D; Champion B; McNeish I
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34893524
[TBL] [Abstract][Full Text] [Related]
19. Advances in the management of epithelial ovarian cancer.
Berkenblit A; Cannistra SA
J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
[TBL] [Abstract][Full Text] [Related]
20. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S; van Stein R; Sikorska K; Barton D; Perrin L; Brennan D; Zivanovic O; Mosgaard BJ; Fagotti A; Colombo PE; Sonke G; Driel WJV;
Int J Gynecol Cancer; 2020 Jun; 30(6):888-892. PubMed ID: 32205449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
